Comparison of Two PPOS Models for Pituitary Suppression

Status Not yet recruiting

Clinical Trial Summary

The scarcity of evidence regarding the interchangeable use of different progestogens poses challenges, particularly in international egg donation and fertility preservation programs where standardizing protocols is crucial for achieving consistent efficacy, efficiency, and safety outcomes. Consequently, there's a pressing need for clinical studies to assess the effects of various progestogens on clinical outcomes in controlled ovarian hyperstimulation cycles. This study, a pioneering effort, aims to compare the effects of two progestogens on oocyte performance, safety, and efficiency in an egg donation program involving young, healthy, normo-responding patients.

Clinical Trial Description

This is a multicenter, randomized, controlled clinical study comparing two different progestogens for pituitary suppression in normo-responding patients undergoing controlled ovarian hyperstimulation (COH) for egg donation. Patients will be recruited on the day they begin the egg donation program. Before inclusion, patients must meet all inclusion and exclusion criteria and provide written informed consent. Each patient will be assigned a patient code based on the treatment group they are included in. Treatment with the assigned progestogens will start on the first day of COH. The standard protocol for egg donation will be followed, including stimulation with FSHr (Puregon®), pituitary suppression with either Medroxyprogesterone acetate (Progevera®) or Desogestrel (Cerazet®), and trigger with GnRH agonist (Triptorelin acetate, Decapeptyl®) 36 hours before oocyte retrieval. Patients will continue taking the assigned progestogen throughout the COH period. Oocyte quality will be assessed based on maturity and morphology, with mature oocytes classified as normal or good quality and abnormal oocytes categorized into intracytoplasmic and extracytoplasmic abnormalities. Quality assessment will be performed by two blinded embryologists. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06304220
Study type	Interventional
Source	NextFertility
Contact	Luis Quintero
Phone	+34 963160240
Email	luis.quintero@next-clinics.com
Status	Not yet recruiting
Phase	N/A
Start date	July 2024
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05969574` - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting	`NCT05358483` - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting	`NCT05969795` - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support	Phase 1
Recruiting	`NCT06051201` - Innovation for Small-scale Experiments: ReceptIVFity Test	N/A
Completed	`NCT03177538` - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders	Phase 4
Completed	`NCT03638856` - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy	N/A
Completed	`NCT04052464` - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn	`NCT04753736` - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC	N/A
Completed	`NCT03349905` - Deferred Versus Fresh Embryo Transfers	N/A
Completed	`NCT05076981` - Progesterone Levels During Ovulation and Luteal Phase
Completed	`NCT04096027` - Cabergoline Before or After Oocyte Collection for Follicular Resolution	Phase 4
Recruiting	`NCT05980091` - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.	Phase 1
Terminated	`NCT01933633` - Improved Fertility After Exercise in Overweight/Obese Women	N/A
Completed	`NCT01202656` - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)	Phase 1/Phase 2
Terminated	`NCT01202643` - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF	Phase 1/Phase 2
Completed	`NCT01408615` - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation	`NCT05698550` - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET	Phase 3
Not yet recruiting	`NCT03910582` - Personalized FET in RIF Patients With Displaced Dating	N/A
Completed	`NCT05440019` - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed	`NCT05130125` - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.